Investors’ appetite for new biotech listings has shown signs of waning this fall, but Oyster Point and RAPT managed to price NASDAQ IPOs within expectations ahead of Thursday’s session, and each posted gains in the...

IGM raises $102M C round IGM Biosciences Inc. (Mountain View, Calif.) raised $102 million in a series C round that included new investors Redmile Group, Janus Henderson Investors, Vivo Capital and an undisclosed U.S.-based healthcare...

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...

FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds,...

Data from 42 evaluable patients with advanced malignant tumors in an open-label, dose-escalation, international Phase I/IIa trial showed that once-daily 25-200 mg oral BMS-986205 for 2 weeks followed by BMS-986205 in combination with Opdivo nivolumab...

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) emerged from stealth mode and disclosed it has raised $119.7 million raised in combined series A and B rounds. CEO Terry Rosen told BioCentury the company expects to move...

The Column Group plans to invest its biggest fund yet in fewer companies. The goal is to infuse enough capital into platform-based newcos that they can turn a blind eye to the capital markets. At...